Antibody-Mediated Immunogenicity Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Following Priming, Boosting, and Hybrid Immunity: Insights From 11 Months of Follow-up of a Healthcare Worker Cohort in Israel, December 2020-October 2021.

Autor: Edelstein M; Ziv Medical Centre, Safed, Israel.; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel., Wiegler Beiruti K; Ziv Medical Centre, Safed, Israel., Ben-Amram H; Ziv Medical Centre, Safed, Israel., Bar-Zeev N; International Vaccine Access Center, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, USA., Sussan C; Ziv Medical Centre, Safed, Israel., Asulin H; Ziv Medical Centre, Safed, Israel., Strauss D; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel., Bathish Y; Ziv Medical Centre, Safed, Israel.; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel., Zarka S; Ziv Medical Centre, Safed, Israel.; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel., Abu Jabal K; Ziv Medical Centre, Safed, Israel.; Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.

Publikováno v: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2022 Aug 24; Vol. 75 (1), pp. e572-e578.